Announcements
- NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting
- NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results
- NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LP
- NGM Bio to Participate in the Cowen 44th Annual Health Care Conference
- NGM Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference
- NGM Bio Announces New Clinical Data from Ongoing Trial of NGM707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and NGM120 to Focus on Rare Conditions with Significant Unmet Need
- NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting®
- NGM Bio to Participate in Upcoming Investor Conferences
- NGM Bio Reports Third Quarter 2023 Financial Results and Provides Business Highlights
- NGM Bio Announces Oral Plenary Presentation of Data from Phase 2b ALPINE 4 Trial of Aldafermin in Compensated Cirrhosis (F4) Due to NASH at Upcoming AASLD The Liver Meeting®
More ▼
Key statistics
As of last trade, NGM Biopharmaceuticals Inc (0IK:MUN) traded at 1.45, 154.39% above the 52 week low of 0.57 set on Nov 22, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.45 |
---|---|
High | 1.45 |
Low | 1.45 |
Bid | 1.45 |
Offer | 1.47 |
Previous close | 1.45 |
Average volume | 0.00 |
---|---|
Shares outstanding | 83.46m |
Free float | 64.29m |
P/E (TTM) | -- |
Market cap | 135.21m USD |
EPS (TTM) | -1.73 USD |
Data delayed at least 15 minutes, as of Mar 28 2024 07:05 BST.
More ▼